[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367534-105":59,"doc-detail-367534-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","management-paradigm-for-ovarian-neuroendocrine-carcinoma-a-systematic-review","Management paradigm for ovarian neuroendocrine carcinoma - a systematic review","","Ovarian neuroendocrine carcinoma (O-NEC) is a rare but highly aggressive malignancy with complex diagnosis and poor outcomes. This systematic review synthesizes management approaches using a comprehensive literature search across PubMed, Science Direct, Wiley, Springer Link, Google Scholar, and Cochrane Central Register of Controlled Trials up to August 1, 2024. Twenty-one eligible studies involving 923 cases were identified, detailing tumor subtypes, immunohistochemical profiles, treatment patterns, and survival, and concluding that prognostic stage at diagnosis is critical.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/management-paradigm-for-ovarian-neuroendocrine-carcinoma-a-systematic-review/367534/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/management-paradigm-for-ovarian-neuroendocrine-carcinoma-a-systematic-review/367534.png","ImageObject",300,407,{"name":92,"@type":93},"วิน","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was the systematic review conducted for O-NEC management?","Question",{"text":112,"@type":113},"A comprehensive search was performed in PubMed, Science Direct, Wiley, Springer Link, Google Scholar, and Cochrane Central Register of Controlled Trials, dated August 1, 2024.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What were the main findings on O-NEC subtypes and immunohistochemical markers?",{"text":117,"@type":113},"The most common subtypes were small-cell and large-cell NEC. Immunohistochemical markers frequently included synaptophysin, chromogranin A, CD56, and NSE.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment approaches were most common and how did outcomes compare?",{"text":121,"@type":113},"Treatment commonly involved surgery alone or surgery plus chemotherapy. No standardized chemotherapy regimen was identified, and survival outcomes were poor, with median overall survival reported between 11 and 23.5 months.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367534,1790538474,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Mantilidewi etal. Journal of Ovarian Research (2025) 18:125 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-025-01701-7](https://doi.org/10.1186/s13048-025-01701-7)  \nREVIEW Open Access  \nManagement paradigm for ovarian neuroendocrine carcinoma: a systematic review  \nKemala Isnainiasih Mantilidewi 1, Gatot Nyarumenteng Adhipurnawan Winarno 1*, Ali Budi Harsono 1, Dodi Suardi 1, Yudi Mulyana Hidayat 1, Andi Kurniadi 1, Siti Salima 1, Febia Erfiandi 1, Aini Sofa Haniah 1 and Nirmala Chandralega Kampan2  \nAbstract  \nIntroduction Neuroendocrine neoplasms (NENs) of the female genital tract are rare, comprising only 1–2% of gynecologic tumors, with ovarian neuroendocrine carcinoma (O-NEC) accounting for less than 1% of all ovarian cancers. Despite its rarity, O-NEC is a highly aggressive tumor with poor prognosis and significant diagnostic complexity, warranting focused clinical attention and demand greater awareness to improve diagnostic and therapeutic strategies.  \nMethods This systematic review analyzed management paradigm for O-NEC through a comprehensive search on the databases PubMed, Science Direct, Wiley, Springer Link, Google Scholar and Cochrane Central Register of Controlled Trials that was performed on August 1st, 2024.  \nResults A comprehensive search on August 1st, 2024, identified 21 eligible studies (6 retrospective cohorts, 12 case reports, 3 case series), encompassing 923 cases of O-NEC. The most common subtypes were small-cell (40%) and large-cell (39 . 8%) NEC. Most patients presented with advanced-stage (Stage III–IV: 52%) . Immunohistochemical markers included synaptophysin (84%), chromogranin A (64 . 2%), CD56 (69%), and NSE (77 . 7%) . Treatment varied from surgery alone (35%) or surgery plus chemotherapy (32%) being most common. No standardized regimen of chemotherapy was identified with etoposide/cisplatin and paclitaxel/carboplatin were most frequently used. Survival outcomes were poor, with median overall survival ranging from 11 to 23.5 months. The stage at diagnosis was a crucial prognostic factor.  \nConclusions The O-NEC is a rare, heterogeneous malignancy with diverse histopathology, variable immunohistochemical profiles, and generally poor prognosis. Early-stage disease may be managed with surgery alone, while advanced stages require multimodal treatment including surgery with adjuvant platinum-based chemotherapy. Due to limited cases and predominantly retrospective data, standardized diagnostic and treatment protocols are lacking. Prospective multicenter studies and centralized registries are needed to improve understanding and patient outcomes.  \n*Correspondence:  \nGatot Nyarumenteng Adhipurnawan Winarno [gatot. nyarumenteng@unpad.ac.id](gatot. nyarumenteng@unpad.ac.id)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/.  \nMantilidewi et al. Journal of Ovarian Research (2025) 18:125 Page 2 of 15  \nKeywords Ovary, Neuroendocrine carcinoma, Treatment, Outcomes  \nIntroduction  \nNeuroendocrine neoplasms (NENs) represent a diverse group of epithelial tumors that arise from neuro","cbCaim7jfQD7FFGZ","https://ap.wps.com/l/cbCaim7jfQD7FFGZ","pdf",1947053,15,"English","# Abstract\n# Introduction\n## Neuroendocrine neoplasms in the female genital tract\n## NETs vs NECs: clinical-pathological distinctions\n# Methods\n# Results\n## Study selection and case distribution\n## Subtypes, biomarkers, and treatment patterns\n## Prognosis and survival outcomes\n# Conclusions","[{\"question\":\"How was the systematic review conducted for O-NEC management?\",\"answer\":\"A comprehensive search was performed in PubMed, Science Direct, Wiley, Springer Link, Google Scholar, and Cochrane Central Register of Controlled Trials, dated August 1, 2024.\"},{\"question\":\"What were the main findings on O-NEC subtypes and immunohistochemical markers?\",\"answer\":\"The most common subtypes were small-cell and large-cell NEC. Immunohistochemical markers frequently included synaptophysin, chromogranin A, CD56, and NSE.\"},{\"question\":\"What treatment approaches were most common and how did outcomes compare?\",\"answer\":\"Treatment commonly involved surgery alone or surgery plus chemotherapy. No standardized chemotherapy regimen was identified, and survival outcomes were poor, with median overall survival reported between 11 and 23.5 months.\"}]","Management paradigm for ovarian neuroendocrine carcinoma - a systematic review | PDF",1790171253,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0ae1c4ff4713d49b811a98b84333a87.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/383c8d9cf11be1dd9b70f50904d4b16c.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90a55e30a855f4445352cd6aef8f591a.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bda054e3e1df21013ec4dbb359302afb.webp",980,1306]